APPROVED_FOR_MARKETINGNCT05592743
Vorasidenib Expanded Access Program
Studying Oligodendroglioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Servier
- Principal Investigator
- Jonathan Dewey, MDServier Pharmaceuticals, LLC
- Intervention
- Vorasidenib(drug)
- Eligibility
- 12 years · All sexes
Collaborators
Servier Pharmaceuticals, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05592743 on ClinicalTrials.govOther trials for Oligodendroglioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06989086FearLess in NeuroOncologyVirginia Commonwealth University
- ACTIVE NOT RECRUITINGPHASE1NCT06254326ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult PatientsUniversity of Florida
- RECRUITINGPHASE2NCT05512351Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaHenan Provincial People's Hospital
- RECRUITINGNANCT05190172PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmasOslo University Hospital
- RECRUITINGPHASE3NCT04702581A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than SurgeryHospices Civils de Lyon
- RECRUITINGPHASE3NCT05331521A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).University Hospital Heidelberg
- ACTIVE NOT RECRUITINGPHASE2NCT03969706Abemaciclib in Patients with OligodendrogliomaStephen Bagley, MD, MSCE